• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对2024年公共卫生服务研究不当行为政策最终规则的思考。

Reflections on the 2024 Final Rule on Public Health Service Policies on Research Misconduct.

作者信息

Phillips Trisha, Earl Jake

机构信息

Department of Political Science, West Virginia University, Morgantown, USA.

Department of Philosophy, Georgetown University, Washington, USA.

出版信息

Account Res. 2025 Jul;32(5):675-692. doi: 10.1080/08989621.2025.2451168. Epub 2025 Jan 28.

DOI:10.1080/08989621.2025.2451168
PMID:39873411
Abstract

BACKGROUND

The Office of Research Integrity (ORI) of the U.S. Department of Health and Human Services (HHS) recently issued the 2024 Final Rule on Public Health Service Policies on Research Misconduct (42 CFR 93), the first major revision of the regulation in nearly twenty years. Much of the commentary published about the 2024 Final Rule has focused on its impacts on research misconduct proceedings at institutions receiving Public Health Service funding. But formally addressing research misconduct is just one part of a larger effort needed to promote research integrity and the responsible conduct of research, and the new rule has the potential to affect this larger effort.

METHODS

This article examines the evolution of the 2024 Final Rule and analyzes five changes with the potential to have broader impacts on cultures of research integrity at U.S. institutions. We consider changes that did and not happen in development from the 2005 Final Rule to the 2023 Notice of Proposed Rulemaking (NPRM) and the 2024 Final Rule.

RESULTS

We identify three changes that the research community should welcome (partnership between ORI and the regulated community, identifying potential respondents, and defining research integrity), one change of concern (redefining plagiarism), and one change that might or might not be welcome (promoting research integrity and the responsible conduct of research).

CONCLUSIONS

Although there is cause for concern about some of the 2024 Final Rule's potential implications for cultures of research integrity at US institutions, the positive changes support an optimistic outlook. In the coming years, it will be critical for HHS, ORI, the research community, and other stakeholders to work hand-in-hand to build on the progress made in the 2024 Final Rule to prevent and address research misconduct as part of a comprehensive effort to promote research integrity and the responsible conduct of research.

摘要

背景

美国卫生与公众服务部(HHS)的研究诚信办公室(ORI)最近发布了《2024年公共卫生服务研究不当行为政策最终规则》(42 CFR 93),这是该法规近二十年来的首次重大修订。关于《2024年最终规则》发表的许多评论都集中在其对接受公共卫生服务资金的机构的研究不当行为程序的影响上。但正式处理研究不当行为只是促进研究诚信和负责任的研究行为所需的更大努力的一部分,新规则有可能影响这一更大的努力。

方法

本文考察了《2024年最终规则》的演变,并分析了五项可能对美国机构的研究诚信文化产生更广泛影响的变化。我们考虑了从《2005年最终规则》到《2023年拟议规则制定通知》(NPRM)以及《2024年最终规则》制定过程中发生和未发生的变化。

结果

我们确定了研究界应该欢迎的三项变化(ORI与受监管社区之间的伙伴关系、确定潜在回应者以及定义研究诚信)、一项令人担忧的变化(重新定义剽窃)以及一项可能受欢迎也可能不受欢迎的变化(促进研究诚信和负责任的研究行为)。

结论

尽管《2024年最终规则》对美国机构的研究诚信文化的一些潜在影响令人担忧,但积极的变化支持了乐观的前景。在未来几年,HHS、ORI、研究界和其他利益相关者携手合作,在《2024年最终规则》取得的进展基础上再接再厉,将预防和处理研究不当行为作为促进研究诚信和负责任的研究行为的全面努力的一部分,这将至关重要。

相似文献

1
Reflections on the 2024 Final Rule on Public Health Service Policies on Research Misconduct.对2024年公共卫生服务研究不当行为政策最终规则的思考。
Account Res. 2025 Jul;32(5):675-692. doi: 10.1080/08989621.2025.2451168. Epub 2025 Jan 28.
2
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
"Just Ask What Support We Need": Autistic Adults' Feedback on Social Skills Training.“只需询问我们需要什么支持”:成年自闭症患者对社交技能培训的反馈
Autism Adulthood. 2025 May 28;7(3):283-292. doi: 10.1089/aut.2023.0136. eCollection 2025 Jun.
6
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
The measurement and monitoring of surgical adverse events.手术不良事件的测量与监测
Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220.
10
NIH Consensus Statement on Management of Hepatitis C: 2002.美国国立卫生研究院关于丙型肝炎管理的共识声明:2002年。
NIH Consens State Sci Statements. 2002;19(3):1-46.